Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan
ConclusionsApplying the Japanese cancer threshold of USD75,000 –150,000/QALY, NIVO + Chemo was not cost-effective for patients with advanced or metastatic HER2-negative GC/GEJC/EAC in Japan from the perspective of healthcare payer.
Source: Journal of Gastroenterology - Category: Gastroenterology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Databases & Libraries | Esophagus Cancer | Gastric (Stomach) Cancer | Gastroenterology | HER2 | Japan Health | Study